Prostate Specific Antigen (PSA)

Incidence of Early Stage Prostate Cancer Lower After USPSTF Recommendation Against PSA Testing

Incidence of Early Stage Prostate Cancer Lower After USPSTF Recommendation Against PSA Testing

By

Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.

Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer

Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer

By

Screening PSA levels at midlife could identify men who are at greater risk of developing prostate cancer later in life and who should be monitored more closely.

Midlife PSA Levels Can Predict Future Lethal Prostate Cancer

Midlife PSA Levels Can Predict Future Lethal Prostate Cancer

PSA levels in midlife strongly predict future lethal prostate cancer risk in U.S. cohort.

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

By

New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.

Urine Test Accurately Identifies Tumor Grade in Prostate Cancer

Urine Test Accurately Identifies Tumor Grade in Prostate Cancer

By

A new urine assay that can detect genetic changes correlated with prostate cancer correctly identified cancer grade in 92% of men with elevated PSA levels and high-grade cancers.

Rates of Nonrecommended Screenings for Prostate and Breast Cancers Is High Among Older Patients

By

Among persons 65 years or older with limited life expectancies of less than 10 years, an estimated 15.7% may have undergone nonrecommended screenings for prostate and breast cancers.

Prostate Cancer Screening and Treatment Information Inadequate for Most Men

Prostate Cancer Screening and Treatment Information Inadequate for Most Men

By

Important discussions about prostate cancer screening and treatment are not occurring between men and their health care team.

Active Surveillance Criteria for Early Prostate Cancer May Not Be Accurate in African American Men

Active Surveillance Criteria for Early Prostate Cancer May Not Be Accurate in African American Men

By

African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.

Repeating PSA Test in Select Patients Can Mitigate Controversial Issues in Prostate Cancer Screening

Repeating PSA Test in Select Patients Can Mitigate Controversial Issues in Prostate Cancer Screening

By

Some task forces advocate abandoning the use of the screening PSA test because it leads to unnecessary prostate biopsies. Canadian researchers show that repeating the test in select patients can reduce the number of biopsies.

Rates of PSA Screening and Early Stage Prostate Cancer Are Declining

Rates of PSA Screening and Early Stage Prostate Cancer Are Declining

By

The impact on PSA screening and prostate cancer incidence before and after the 2012 USPSTF screening recommendations were examined in two recent studies.

New Blood Test Improves Screening for Prostate Cancer

New Blood Test Improves Screening for Prostate Cancer

By

A new test is better at detecting aggressive prostate cancer than measuring PSA levels. The new test discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies.

Expectant management of very low-, low-risk prostate cancer is effective, but underused

Expectant management of very low-, low-risk prostate cancer is effective, but underused

Using watchful waiting or active surveillance to monitor men with very low- and low-risk prostate cancer is effective in many patients with localized tumors and could prevent aggressive and unnecessary treatments.

Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detection

Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detection

By

A new test that employs urine analysis demonstrated improved prostate cancer detection over traditional models based on prostate-specific antigen (PSA) levels.

Study finds $1 test using gold nanoparticles outperforms PSA screen for prostate cancer

Study finds $1 test using gold nanoparticles outperforms PSA screen for prostate cancer

By

An inexpensive, quick-result test has been shown in recently published studies to be more sensitive and more exacting than the current standard test for early stage prostate cancer.

Early evidence of increase in higher-risk prostate cancer deaths seen in analysis of data

By

A retrospective analysis of patient data found the proportion of men with diagnoses of intermediate- and high-risk prostate cancer increased by nearly 6% between 2011 and 2013.

Patients with detectable PSA after prostatectomy should receive more aggressive radiation therapy

Patients with detectable PSA after prostatectomy should receive more aggressive radiation therapy

By

Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy are advised to receive more aggressive radiation therapy treatment, according to a study.

Study examines vaccine therapy in prostate cancer with rising prostate-specific antigen (PSA) levels

By

A vaccine therapy designed to boost the body's immune response may join available early treatment options for prostate cancer.

Most internet sites on prostate cancer disagree with expert panel's recommendations

Most internet sites on prostate cancer disagree with expert panel's recommendations

By

Less than 20 percent of top-ranked health sites advise against screening for prostate cancer, a recommendation made by the USPSTF.

Protein in prostate biopsies signals increased risk of cancer

By

The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. This discovery is likely to help physicians to decide how closely to monitor men who are potentially at risk for prostate cancer, which is one of the most confusing and controversial dilemmas in health care.

Prostate cancer grade usually does not progress over time

By

The proportion of men with advanced-stage prostate tumors at diagnosis has dropped dramatically since the widespread implementation of PSA screening, but the proportion of men with aggressive cancers at diagnosis has not changed substantially.

'Index patients' aid mCRPC guideline

'Index patients' aid mCRPC guideline

The AUA developed its new clinical guideline on castration-resistant prostate cancer by creating six index patients to represent the most common clinical scenarios encountered when managing the disease.

New prostate cancer screening guidelines from AUA emphasize targeted patient screening

By

New guidelines from the American Urological Association advise men aged 55 to 69 years who are considering prostate cancer screening to talk with their doctors about the benefits and harms of testing.

Most older men receive treatment for screen-detected prostate cancer

Many older men who are found to have prostate cancer after PSA screening receive treatment despite advancing age, poor health, or low-risk disease.

ACP: Harms of PSA testing outweigh benefits for many men

The American College of Physicians (ACP) recommends against prostate-specific antigen (PSA) screening for men older than age 69 and many others.

Alternative PSA screening strategies could reduce harm

Alternative PSA screening strategies could reduce harm

Use of biennial strategy with longer interval for low PSA levels reduces tests, false-positive results.

Change in PSA levels over time is a more accurate predictor of aggressive prostate cancer

By

A recent study showed evaluating prostate-specific antigen measurements taken over time improves the accuracy of aggressive prostate cancer detection compared with a single measurement of PSA.

Doctors' use of informed decision-making for PSA testing varies

Doctors' use of informed decision-making for PSA testing varies

Physicians' practice styles related to informed decision-making for prostate-specific antigen (PSA) screening are linked to their personal beliefs about screening.

Targeted biopsy detects more prostate cancers

A clinic-based technique of targeted biopsy using MRI and ultrasound may improve the diagnosis and management of prostate cancer.

New targeted therapy for prostate cancer has anti-tumor activity in phase I trial

By

Levels of circulating tumor cells and of prostate specific antigen were reduced by a new drug in patients who had already failed previous chemotherapy and hormone treatments.

Watchful waiting offers more quality years than prostatectomy

Compared with prostatectomy, surveillance will likely reduce prostate cancer-specific survival only slightly and greatly enhance quality of life.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs